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sation and committee decisions. These data were analysed to
determine the impact of the policy measures. Policy changes
included increased patient co-payments, mandatory 12.5% price
cut with generic entry, a weighted average monthly treatment
cost price adjustment mechanism. The Pharmaceutical Beneﬁts
Advisory Committee controls recommendations to government
concerning the funding of new drugs. RESULTS: The level 
of acceptance of new drugs that are submitted on a cost-
effectiveness basis has fallen to approximately 20%. The impact
of patient co-payment on reducing the volume of units sold
nationally was estimated to be 5–10%. The effect of price 
reduction initiatives in 2005 on Pharmaceutical Beneﬁts Scheme
expenditure was estimated at 3–4% of total spending. CON-
CLUSIONS: These initiatives have been very effective in restrict-
ing national drug expenditures growth. For most of the 1990s
and into this decade, total expenditure has grown more than
10% per annum. By the end of 2005 this had fallen to well below
5%.
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OBJECTIVE: To identify the impact and persistence of bariatric
surgery on health outcomes and pharmacological treatments
among obese patients. METHODS: A comprehensive analysis of
4322 patients with a diagnostic of obesity (ICD-9-CM = 278)
and a CPT code of bariatric surgery (43,842, 43,843, 43,846,
43,847, S2085) was conducted using US administrative claims
data covering 5.0 million lives. The 50 most frequent 3 digit
ICD-9-CM codes prior to surgery were analyzed along with cor-
responding pharmacological treatments. Diagnostics and phar-
macological treatment were then compared in the 90 days
preceding the surgery and eight 90 day post-surgery periods
(days 30–120 to days 660–750). Frequency counts pre- and post
surgery were performed using 3 digit ICD-9-CM codes for 
diagnostics and AHFS (American Hospital Formulary Service)
therapeutic classes and compared using chi-squared tests.
RESULTS: Cardiovascular disease, diabetes, respiratory disease
(and asthma in particular), joint and muscle disease, and psy-
chiatric disorders prevalence fell monotonically over the two
year period observed (mean age = 43.2, 16.4% male). Two years
following surgery, cardiovascular disease prevalence decreased
from 40.4% to 5.7%), diabetes mellitus from 18.6% to 3.1%,
respiratory disease from 45.0% to 3.2% with asthma dropping
from 6.7% to under 1%, diseases of the joints and muscles from
24.7% to 7.4%, and psychiatric disorders from 12.1% to 3.7%.
Anemia diagnoses increased from 4.1% to 8.9% after 210 days,
but decreased back to 3.6% after 750 days. Treatment frequency
with insulin and oral antidiabetics decreased from 4.4% to 0.5%
and from 16.0% to 1.8%, respectively. Treatment frequency for
cardiovascular diseases (Ace inhibitors, calcium channel block-
ers, diuretics, betablockers, and other hypotensives) fell from
42.1% to 10.1%. Hypolipidemic use also dropped from 12.6%
to 1.9%. All differences between pre- and post surgery propor-
tions are statistically signiﬁcant (P = 0.05). CONCLUSION:
Bariatric surgery is associated with signiﬁcant improvements in
health outcomes and reduced pharmacological utilization for
major disease categories.
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OBJECTIVES: This study examines the factors that inﬂuence
generic entry upon patent expiration of branded drugs, speciﬁ-
cally focusing on the drug’s proﬁtability as a generic ﬁrm’s incen-
tive to enter as well as additional patents ﬁling as a strategic entry
barrier tool by patent holders. METHODS: For 138 drugs
(approved through NDA process between 1970 and 1990)
whose initial patent expired over the period 1994–2003, the
expiration dates of all related patents listed and their generic
version’s approval dates (if generic entry happened) were
obtained from the FDA. At different follow-up time point—6,
12, 18, and 24 months after the initial patent expiration, probit
analyses of the likelihood of generic entry were done to identify
the determinants of the entry. Additionally, we examined the
relationship between total number of patents listed and the
drug’s proﬁtability using negative binomial regression analysis to
investigate whether patent holders ﬁled more patents for future
top-selling products. RESULTS: Top-selling drugs as well as the
drugs for geriatric care were more likely to attract generic entry
at every time point (Relative Risk (RR) for top-selling drugs =
33.84, 6.76, 6.04, and 3.90; RR for geriatric drug = 3.97, 2.35,
1.82, and 1.43 respectively). The likelihood of generic entry
increased as the initial patent expiration year increased (p <
0.05). Generic competition was less likely to occur under the
presence of any unexpired additional patent(s) at each time point
(RR = 0.13, 0.33, 0.30 and 0.32). Top-selling drugs had more
patents compared to non-top-selling drugs (p < 0.000). CON-
CLUSIONS: Delay in generic competition was associated with
patent holder’s intention to extend patented period by ﬁling more
patents. The generic industry has targeted top-selling products
and future-growing market as the population ages. Generic com-
petition increased under “favoring generics policy” and “cost
containment efforts” in last decade.
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OBJECTIVE: Approximately 30% of elderly do not have pre-
scription drug coverage. To remedy this problem, the Medicare
Modernization Act was recently passed. Surprisingly, little is
known about how drug coverage will affect health. The goal of
this paper is to obtain estimates of “causal effects” of prescrip-
tion drug coverage on drug use, inpatient visits and health of the
elderly. METHODS: The primary data source used in the analy-
ses is the Medicare Current Beneﬁciary Survey (MCBS), Cost and
Use ﬁle from Centers for Medicare and Medicaid Services (CMS)
for years 1992–2000. Two empirical approaches were used to
account for non random sorting into drug coverage: ﬁxed-effects
and instrumental variables (IV). The Fixed-effect approach uses
longitudinal data and controls for unmeasured person-speciﬁc
effects that may confound the relationships of interest. IV uses
arguably exogenous variation in prescription drug coverage to
obtain estimates of the relationships of interest. RESULTS:
Between 1992–2000 approximately 25% of the elderly in the
sample gained some level of prescription drug coverage. Esti-
mates showed that after accounting for the non-random nature
of prescription drug coverage, drug coverage, particularly public
coverage, signiﬁcantly increased the utilization of prescription
drugs (~13% higher utilization), but has no signiﬁcant discern-
able effect on the use inpatient visits or health, as measured by
